IN2015DN00636A - - Google Patents

Info

Publication number
IN2015DN00636A
IN2015DN00636A IN636DEN2015A IN2015DN00636A IN 2015DN00636 A IN2015DN00636 A IN 2015DN00636A IN 636DEN2015 A IN636DEN2015 A IN 636DEN2015A IN 2015DN00636 A IN2015DN00636 A IN 2015DN00636A
Authority
IN
India
Prior art keywords
aptamer
epcam
present disclosure
disclosure relates
specifically bind
Prior art date
Application number
Other languages
English (en)
Inventor
Wei Duan
Original Assignee
Univ Deakin
Wei Duan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012903333A external-priority patent/AU2012903333A0/en
Application filed by Univ Deakin, Wei Duan filed Critical Univ Deakin
Publication of IN2015DN00636A publication Critical patent/IN2015DN00636A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
IN636DEN2015 2012-08-02 2013-08-02 IN2015DN00636A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012903333A AU2012903333A0 (en) 2012-08-02 EpCAM Aptamer for Detection of Cancer Stem Cells
PCT/AU2013/000851 WO2014019025A1 (fr) 2012-08-02 2013-08-02 Aptamères epcam pour la détection de cellules souches cancéreuses

Publications (1)

Publication Number Publication Date
IN2015DN00636A true IN2015DN00636A (fr) 2015-06-26

Family

ID=50026988

Family Applications (1)

Application Number Title Priority Date Filing Date
IN636DEN2015 IN2015DN00636A (fr) 2012-08-02 2013-08-02

Country Status (16)

Country Link
US (1) US9567586B2 (fr)
EP (1) EP2880163B1 (fr)
JP (1) JP6297034B2 (fr)
KR (1) KR20150083075A (fr)
CN (1) CN104854243B (fr)
AU (1) AU2013299332B2 (fr)
BR (1) BR112015002286A2 (fr)
CA (1) CA2880590C (fr)
HK (1) HK1213941A1 (fr)
IL (1) IL237038A0 (fr)
IN (1) IN2015DN00636A (fr)
MX (1) MX2015001441A (fr)
NZ (1) NZ704718A (fr)
SG (1) SG11201500663RA (fr)
WO (1) WO2014019025A1 (fr)
ZA (1) ZA201501317B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022165286A1 (fr) * 2021-01-29 2022-08-04 Base Pair Biotechnologies, Inc. Ligands fonctionnels dirigés contre la toxine pertussique
CA2959386C (fr) * 2014-08-29 2024-06-04 Lee Adam Wheeler Methodes et compositions pour le traitement du cancer
KR101641920B1 (ko) * 2014-09-05 2016-07-22 한국생명공학연구원 EpCAM에 특이적으로 결합하는 핵산 앱타머 및 이의 용도
EP3256593B1 (fr) * 2015-02-11 2020-03-25 Deakin University Aptamères d'epcam et conjugués desdits aptamères
CN105779458B (zh) * 2016-03-23 2020-03-17 苏州方舟生物医药有限公司 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物
CN107875140A (zh) * 2016-09-30 2018-04-06 复旦大学 一种双靶向药物递送系统及其在制备肿瘤治疗制剂中的应用
WO2019018497A1 (fr) * 2017-07-18 2019-01-24 President And Fellows Of Harvard College Administration intracellulaire au moyen d'un criblage cellulaire assisté par microfluidique (macs)
KR102212149B1 (ko) * 2019-03-28 2021-02-04 부산대학교 산학협력단 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도
CN110184272B (zh) * 2019-04-01 2021-03-30 福州大学 一种新型环状三元适配体及其合成方法和应用
EP3987032A4 (fr) * 2019-06-21 2024-01-10 The Children's Medical Center Corporation Méthodes et compositions permettant le traitement du cancer
CN110261359B (zh) * 2019-06-27 2022-01-28 复旦大学 一种基于激光共聚焦显微镜的癌症标志物成像方法
CN110592093B (zh) * 2019-09-10 2023-08-25 上海交通大学医学院附属仁济医院 一种能够识别EpCAM蛋白的核酸适体及其制备方法与应用
EP3868884A1 (fr) * 2020-02-19 2021-08-25 Aarhus Universitet Procédé de sous-typage du cancer de la vessie à l'aide d'aptamères
CA3217459A1 (fr) * 2021-05-06 2022-11-10 Spyro Mousses Compositions pour inhiber la croissance de cellules ciblees
CN114990124B (zh) * 2022-06-22 2023-09-05 中国科学院苏州纳米技术与纳米仿生研究所 膜蛋白靶标cd44的核酸适配体、其筛选方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105104A1 (en) * 2007-03-05 2010-04-29 On-Chip Cellomics Consortium Chip for sampling cell component, system for analyzing cell component and method of analyzing cell component using the same
EP2159286A1 (fr) * 2008-09-01 2010-03-03 Consiglio Nazionale Delle Ricerche Procédé pour obtenir des aptamères d'oligonucléotide et utilisations associées
WO2013003898A1 (fr) * 2011-07-07 2013-01-10 Clinical Genomics Pty. Ltd Procédé pour de détection d'un cancer chez un patient

Also Published As

Publication number Publication date
IL237038A0 (en) 2015-03-31
NZ704718A (en) 2017-09-29
SG11201500663RA (en) 2015-02-27
US9567586B2 (en) 2017-02-14
AU2013299332B2 (en) 2018-08-09
EP2880163A1 (fr) 2015-06-10
BR112015002286A2 (pt) 2017-07-04
WO2014019025A1 (fr) 2014-02-06
AU2013299332A1 (en) 2015-02-26
CA2880590C (fr) 2020-10-06
JP6297034B2 (ja) 2018-03-20
CN104854243A (zh) 2015-08-19
MX2015001441A (es) 2015-09-23
KR20150083075A (ko) 2015-07-16
ZA201501317B (en) 2016-07-27
HK1213941A1 (zh) 2016-07-15
CA2880590A1 (fr) 2014-02-06
EP2880163B1 (fr) 2018-11-21
US20150197755A1 (en) 2015-07-16
CN104854243B (zh) 2018-01-19
EP2880163A4 (fr) 2016-03-09
JP2015530081A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
IN2015DN00636A (fr)
IL251697A0 (en) Antibodies against 3erbb and their uses
HK1208163A1 (en) Drug-conjugates, conjugation methods, and uses thereof
IN2015DN00634A (fr)
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
CA141065S (en) Dual c clip
ZA201407927B (en) Anti-egfr antibodies and uses thereof
GB201115529D0 (en) Antibodies, uses and methods
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
GB201115280D0 (en) Antibodies, uses and methods
IN2015KN00007A (fr)
WO2013021279A3 (fr) Anticorps fortement galactosylés
AU342351S (en) Automobile
HK1199269A1 (en) Anti-asic1 antibodies and uses thereof -asic1
EP2909325A4 (fr) Micro-organismes et procédés d'amélioration de la disponibilité d'équivalents réducteurs en présence de méthanol, et de production de succinate correspondant
MY168166A (en) Polymer and Composition Including Same, and Adhesive Composition
IN2014DN06104A (fr)
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
CA141066S (en) Dual c clip
IL235609B (en) Broadband repeater with low latency, and methods
EP2900693A4 (fr) Anticorps médiant adcc, combinaisons et applications associées
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия